Ascentage Pharma Group International (AAPG) Enterprise Value (2022 - 2025)

Ascentage Pharma Group International (AAPG) has reported Enterprise Value for 4 consecutive years, with -$348.3 million the latest figure, recorded in Q4 2025.

• Quarterly Enterprise Value fell 183.27% year-over-year to -$348.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$348.3 million (down 183.27% YoY) and the FY2025 annual result came in at -$343.7 million, down 179.52% from the prior year.
• Enterprise Value declined to -$348.3 million in Q4 2025 per AAPG's latest filing, from -$231.9 million in the prior quarter.
• Over the last five years, Enterprise Value for AAPG reached as high as -$2.0 million in Q4 2023 and fell as low as -$348.3 million in Q4 2025.
• A 4-year average of -$178.9 million and a median of -$189.2 million in 2022 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2023 — Enterprise Value surged 98.95% — and 2024, when it plunged 6080.84%.
• Year by year, Enterprise Value stood at -$189.2 million in 2022, then jumped by 98.95% to -$2.0 million in 2023, then tumbled by 6080.84% to -$122.9 million in 2024, then sank by 183.27% to -$348.3 million in 2025.
• According to Business Quant data, Enterprise Value over the past three periods registered -$348.3 million, -$231.9 million, and -$122.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.